The purpose of this study is to evaluate mass balance, pharmacokinetics and safety of \[14C\] ABBV-CLS-7262 in healthy, male volunteers following administration of a single oral dose.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
7
Oral Solution
Fortrea Clinical Research Unit Inc.
Madison, Wisconsin, United States
Number of Participants with Adverse Events (AEs)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time frame: Up to approximately 30 days from last dose.
Maximum observed concentration (Cmax)
Cmax will be assessed.
Time frame: Up to approximately Day 15 from last dose
Time to Cmax (peak time, Tmax)
Tmax will be assessed.
Time frame: Up to approximately 15 days from last dose
Terminal phase elimination half-life (t1/2)
Terminal phase elimination half-life (t1/2) will be assessed.
Time frame: Up to approximately 15 days from last dose
Area under the plasma concentration-time curve (AUC) from time 0 to the time of the last measurable concentration (AUCt)
AUCt will be assessed.
Time frame: Up to approximately 15 days from last dose
Percent radioactivity excreted
Percentage total radioactivity
Time frame: Up to approximately 15 days from last dose
Identification of metabolites excreted
Identification of the major metabolites
Time frame: Up to approximately 15 days from last dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.